Abivax (ABVX) Cash from Discontinued Operations (2025 - 2026)

Abivax's (ABVX) quarterly Cash from Discontinued Operations came in at 59144899.5 in Q1 2026, down 68.96% year-on-year from 190563599.23 in Q1 2025, and down 68.96% quarter-over-quarter from 35004610.38 in Q1 2025.

Abivax (ABVX) Cash from Discontinued Operations (2025 - 2026) Analysis & Trends

Abivax's Cash from Discontinued Operations history runs 2 years deep, the most recent figure standing at 59144899.5 for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Abivax 9.98 Bn 9.98 Bn - -59.14 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -59.14 Mn
Mar 31, 2026 -59.14 Mn
Mar 31, 2025 -35.00 Mn
Mar 31, 2025 -35.00 Mn